Kornimate/medical-research-clean huggingface dataset:
treatment of major depressive disorder in the uk using tms therapy

Conditions: Major Depressive Disorder

Summary: the major objective of this observational study is to describe clinical outcomes of patients in the uk receiving treatment with the neurostar tms therapy system in routine clinical practice.

this is a single-center, naturalistic, observational study following the use of the neurostar® advanced therapy system and assessment of clinical outcome. the goal is to collect, analyze and report information as aggregated summaries on participants receiving treatment with the neurostar® advanced therapy system.

Eligibility criteria:
inclusion criteria: 1. men or women, age 22 - 70, out-patient 2. participants who meet the dsm-5 clinical diagnostic criteria, in the opinion of the treating clinician, for primary diagnosis of unipolar, non-psychotic mdd. the intended treatment plan uses the labeled treatment parameters for tms as described in the neurostar® system 3. women of child bearing potential must be using a medically accepted reliable means of contraception (for oral contraceptive medication: must be in use for at least 3 months) 4. women of childbearing potential must have a negative pregnancy test at screening using urine dipstick 5. participants must have the capacity to consent to all tests and examinations required by the protocol and must sign a written informed consent document to participate in the study. exclusion criteria: 1. history of seizures or increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure or history of significant head trauma with loss of consciousness for ≥ 5 minutes 2. inability to locate and quantify a motor threshold as defined in the protocol 3. conductive, ferromagnetic, or other magnetic-sensitive metals implanted in the participant's head within 30 cm of the treatment coil excluding the mouth that cannot safely be removed. examples include: cochlear implants; implanted electrodes/stimulators; aneurysm clips or coils; stents; bullet fragments; jewelry; and hair barrettes 4. any psychiatric disorder which, in the judgement of the investigator, may hinder the participant from completing the procedures required by the study protocol 5. active or inactive implants (including device leads), including deep brain stimulators, and vagus nerve stimulators 6. cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute, unstable cardiac disease 7. known or suspected pregnancy

Keywords: transcranial magnetic stimulation major depressive disorder mdd tms neurostar advanced therapy system repetitive transcranial magnetic stimulation rtms
effect of vildagliptin in type 2 diabetes treated with sulphonylurea and metformin

Conditions: Diabetes

Summary: dual combination therapy with metformin and sulphonylurea is the most commonly used combination regimen to treat patients with type 2 diabetes. but, treatment with the dual combination therapy is often unsuccessful at achieving glycaemic control in patients with type 2 diabetes. in this setting, use of insulin is often the next therapeutic step. recently, dipeptidyl peptidase (dpp)-iv inhibitor is increasingly being used in clinical practice. it is well established that dpp-iv inhibitor improve glycemic control in patients with type 2 diabetes. but, there have been few studies about the glucose lowering effect of dpp-iv inhibitors (vildagliptin) in type 2 diabetes patients on the dual combination therapy with a sulfonylurea agent and metformin.the researchers hypothesized that dpp-iv inhibitor as add-on therapy to combination of a sulfonylurea agent and metformin have favorable glucose lowering effect in type 2 diabetic patients. the researchers plan to investigate the change in hba1c and fasting glucose of 24 weeks treatment with vildagliptin (dpp-iv inhibitor) in combination with a sulfonylurea agent and metformin in type 2 diabetic patients.


Eligibility criteria:
inclusion criteria: * type 2 diabetes * hba1c ≥ 7% * age ≥ 18 exclusion criteria: * contraindication to vildagliptin * pregnant or breast feeding women * type 1 diabetes, gestational diabetes, or diabetes with secondary cause * chronic hepatitis b or c (except healthy carrier of hbv) * liver disease (ast/alt \> 3-fold the upper limit of normal) * renal failure (cr \> 2.0) * cancer within 5 years * not appropriate for oral antidiabetic agent * medication which affect glycemic control * disease which affect efficacy and safety of drugs * other clinical trial within 30 days

Keywords: diabetes vildagliptin insulin c-peptide
taiwan associated genetic and nongenetic small vessel disease

Conditions: Cerebral Small Vessel Diseases; Cadasil; HTRA1-Related Autosomal Dominant Cerebral Angiopathy; COL4A1-Related Brain Small Vessel Disease With Haemorrhage; Fabry Disease; Magnetic Resonance Imaging; Next-generation Sequencing; Stroke

Summary: the tag-svd enrolled patients with clinical and neuroimaging features of cerebral small vessel disease (csvd). all enrolled patients will receive next-generation sequence (ngs) with probes designed to target five candidate csvd genes, and patients will be divided into genetic or non-genetic groups accordingly. their clinical features and outcome will be followed for at least 2 years.


Eligibility criteria:
inclusion criteria: participants must have at least one of the following symptoms/signs or history * stroke (especially small vessel occlusion type of ischaemic stroke, spontaneous ich or young stroke) * cognitive impairment or dementia * gait disturbance * parkinsonism (especially vascular parkinsonism features) * headache (especially migraine) * positive family history of hereditary csvd * mri evidence of csvd (mri may be done for other reasons), including mild to moderate white matter hyper intensity, any lacune, or any cerebral microbleed exclusion criteria: * mri evidence of csvd due to other inflammatory, malignancy, or structural lesions * patients or family members not willing to sign informed consent
monitoring intermittent fasting for human optimization using wearable technology: an n-of-1 study

Conditions: Intermittent Fasting; Healthy; Digital Health

Summary: there is a growing interest in personalized health strategies, including diet, exercise, and fasting regimens, to enhance metabolic fitness. recent research indicates that intermittent fasting (if) is useful not only for weight management, but also for energy production and improvement of metabolic well-being. if can potentially reduce systemic inflammation and help to prevent chronic diseases. if research can also help athletes sustain performance during fasting periods. this prospective study aims to investigate the effects of a human optimization program on an individual\&#39;s metabolic health and overall well-being. this research examines the correlations between continuous glucose monitoring, ketone measurement, exercise routines, heat/cold interventions, diet, supplements and intermittent fasting patterns. the study involves a single participant -the principal investigator- who will adhere to a personalized regimen involving wearable monitoring of metabolic changes, training and intermittent fasting. this research seeks to understand the potential relationships between these factors, contributing to the emerging knowledge on individualized health optimization.


Eligibility criteria:
inclusion criteria: * the principal investigator is the sole participant in this n-of-1 trial: a healthy individual with no chronic diseases or conditions affecting metabolic health. exclusion criteria: * the principal investigator is the sole participant in this n-of-1 trial.

Keywords: continuous glucose monitoring (cgm) intermittent fasting (if) ketone measurement wearable technology exercise routines heat/cold interventions diet and supplements human optimization n-of-1 single participant personalized health digital health sensors
olfactory and trigeminal functions in patients with multiple sclerosis: case-control study

Conditions: Multiple Sclerosis

Summary: the sensation of smell is influenced by the somatosensory and chemesthetic sensati¬ons of the nose: for example, the cooling sensation of menthol or the prickle of carbon dioxide from carbonated drinks. these sensations are mediated in the nose by the trigeminal nerve and there is increasing evidence that trigeminal and olfactory functions are closely linked and potentially interdependent. in addition, trigeminal activation is crucial to the perception of nasal airflow. some researchers speculate about the impact of trigeminal nerve on the entire olfactory sensation and about the presence of some specific "trigeminal cells" into the nose.patients with multiple sclerosis (ms) can suffer from quantitative olfactory disorders that generally are of light entity and do not interfere with daily life activities but it is important to underline that olfactory loss can be an onset sign of the ms. considering the "trigeminal component" in the olfaction, because trigeminal nerve inflammation is quite common in ms patients due to central and peripheral inflammation, it could be possible that these patients suffer from changes in the quantitative, but more in the qualitative smell functions that are generally not identified because poorly investigated.

from a theoretically point of view pain in the trigeminal nerve increases the surrounding perception, including the perception of the odors. it has been shown that by using sweet food it is possible to reduce the level of pain; on the other side, sweet food in contrast to the bitter one was able to reduce the sensation of odor unpleasantness present with pain increase. to date no studies have investigated the relationship between trigeminal inflammation, odors and pain in a cohort of patients with ms. this study aims at investigating the possible correlation between alteration in trigeminal functions and perception of odors using sniffin' stick threshold, detection and identification test and quality smell questionnaire in a sample of healthy patients compared to ms patients.

Eligibility criteria:
inclusion criteria: adult women (age 18 to 55) diagnosed with multiple sclerosis using the 2017 mcdonald criteria under treatment with disease modifying therapy (dmts) with or without trigeminal concerns, or newly diagnosed with ms exclusion criteria: * chronic rhinosinusitis with and without nasal polyposis; current allergic rhinitis; other nasal issues that lead to olfactory dysfunction * anamnestic covid with incomplete recovery * neurodegenerative disorders (parkinson, alzheimer, fronto-temporal dementia, cognitive impairment and brain vascular diseases) * history of stroke in the last three years * depression or any psychiatric condition * intake of drugs with sedating side effects * major health issues that might affect olfactory function (e.g., significant renal insufficiency, uncontrolled diabetes) * chronic alcoholism / drug abuse * severe head trauma * severe facial injuries * smoker over 20 cigarettes day or smoking from more than 15 years
electrical stimulation with different currents: the effects on force, tolerance and fatigue in healthy subjects

Conditions: Healthy

Summary: muscle strength is the amount of force generated by muscle contraction. it could be measured with an isometric dynamometer. this is a validated tool that could be used to measure maximal voluntary isometric contraction (mvic) and maximal electrical induced contraction (meic). it is claimed that higher meic values will result in more force gained. if a current is more tolerated it will be easier to achieve better meic values. tolerance to an electrical stimulation could be measured with the visual analogue scale (vas). a ratio between normalized meic / vas is often used, implying that the current is better with a higher ratio. muscle fatigue is defined as a temporary loss or decrease in force-generating ability due to previous contractions. it is claimed that medium frequency neuromuscular electrical stimulation (nmes) generates more fatigue than low frequency currents. aussie is a medium-frequency alternating current, sinusoidal waveform, 1 khz carrier frequency. neo-russian is a medium-frequency current, rectangular biphasic symmetrical waveform, 2,5 khz carrier frequency. rectangular biphasic symmetrical (rbs) waveform is a type of low pulsed current (lpc), claimed to be better than classical russian current. purpose: as it has been claimed that lpc is better in meic and tolerance, the aim of this study is to compare it with two newer medium frequency currents in terms of meic, tolerance and fatigue. methods: thirty male subjects, right leg dominant, will receive randomly the 3 types of electrical stimulation. before that, the mvic will be measured for data normalization. the mvic and meic will be measured with an isometric dynamometer. in both measurements, subjects will be asked to perform three reps (5 sec work x 120 sec rest) and the best one will be used. whenever the third one was the best, additional measurements will be taken until a decrease in torque will be obtained to determine the maximum. to apply aussie electrical stimulation, an aussie sport (ibramed) will be used. to apply neo-russian, a neurodyn iii (ibramed) will be used. to apply rbs, a genesy (globus) will be used. the vas will be used to assess tolerance to each treatment. one week later, the subjects will receive, randomly, a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest) of electrical stimulation with the three types of current. the data will be normalized with the mvic and the reps equal or below 50 % of the first rep will be considered as a fatigue rep.


Eligibility criteria:
inclusion criteria: * healthy volunteers * male * right leg dominant * exercising regularly exclusion criteria: * history of injuries in the right leg * skin lesions * having a pacemaker * having a cardiovascular disease. * having a neurological disorder. * exercise 72 h before the procedure.

Keywords: electrical stimulation muscle strength fatigue assessments, pain
intralipid versus smoflipid in hpn patients

Conditions: Short Bowel Syndrome; Intestinal Fistula; Crohn Disease; Intestinal Obstruction

Summary: this study will randomize all patients who are new to the mayo clinic hpn team to either standard lipid emulsion (intralipid) or smoflipid.

primary aim is to assess the impact to direct/indirect bilirubin. secondary aims will be to assess impact to other liver function studies, metabolic parameters, inflammatory marker, body weight, ability to meet caloric needs through tpn, and ability to obtain appropriate macronutrient composition.

Eligibility criteria:
inclusion criteria: * newly initiated mayo clinic hpn patient * able to provide informed consent * anticipated duration of hpn greater than 3 months, * infusion company is able to provide smoflipid exclusion criteria: * age less than 18 years * pregnant and lactating women * failure to provide consent * patients with underlying liver dysfunction (defined as liver function studies equal to or more than 2 times upper limit of normal) or pathology as determined by primary investigator * patients with active malignancy * patients who are deemed to be on hpn for less than three months * patients who have previous proven addiction and dependence to alcohol/ heavy alcohol and consumption/active use reported during last 12 months. * known hypersensitivity to fish, egg, soybean, or peanut protein, or to any of the active ingredients or excipients in smoflipid * patients who will not be managed by the mayo clinic hpn team * patients who have active infection (as determined by the clinician) at the time of enrollment. * patients who have received smoflipid greater than 4 weeks in the last 12 months prior to enrollment. * patients who have been on tpn greater than 4 weeks in the last 12 months prior to enrollment. * enrolled in another interventional study. * severe hyperlipidemia or severe disorders of lipid metabolism with serum triglycerides more than 1,000 mg/dl.

Keywords: smof intralipid mixed oil emulsion intestinal failure hpn
stenting of the superficial femoral and/or proximal popliteal artery project

Conditions: Atherosclerosis of Native Arteries of the Extremities

Summary: to determine whether the boston scientific nitinol drug-eluting stent shows acceptable performance at 9 months when treating superficial femoral (sfa) and/or proximal popliteal artery (ppa) lesions.


Eligibility criteria:
inclusion criteria: * subjects age 18 and older * subject (or legal guardian if applicable) has signed the consent form and is willing and able to provide consent before any study-specific tests or procedures are performed and agrees to attend all required follow-up visits * chronic, symptomatic lower limb ischemia defined as rutherford categories 2, 3 or 4 * stenotic, restenotic (from angioplasty only, previous treatment with drug coated balloon is not allowed) or occlusive lesion(s) located in the native superficial femoral artery or proximal popliteal artery: 1. degree of stenosis ≥70% by visual angiographic assessment 2. vessel diameter ≥ 4 and ≤ 6mm 3. total lesion length (or series of lesions) ≥30 mm and ≤110 mm * (note: tandem lesions may be treated, provided that the tandem lesion segment can be covered with only one stent) 4. target lesion located at least three centimeters above the inferior edge of the femur * patent infrapopliteal and popliteal artery, i.e., single vessel runoff or better with at least one of three vessels patent (\<50% stenosis) to the ankle or foot

Keywords: atherosclerosis sfa ppa lower extremities stenting paclitaxel
steroid injection in de quervain tenosynovitis

Conditions: De Quervain Disease

Summary: this study is carried out to find out the degree of pain relief achieved with standard treatment as steroid injection as well as its time to onset. it will recruit 50 subjects over a period of 18 months.

the aim of the study is determine how effective these injections are and when will the patient start feeling relief of his/her symptoms.the aim of the study is not to change the current practice, but provide hand surgeons enough data to clarify their patients the expected outcomes and onset timing of the treatment performed.

Eligibility criteria:
inclusion criteria: * \>21 years old exclusion criteria: * pregnancy
study on regeneration of skin defects in diabetic ulcers treated with new electrospun material plcl/fg

Conditions: Diabetic Foot

Summary: prospective cohort studies through clinical trials. obtained a large amount of real-world data to explore the efficacy of plcl/fg dressings for specific clinical applications. published 1 relevant scie paper. provide a large amount of data support for the application of plcl/fg dressing in diabetic foot ulcer wound repair through basic experimental and clinical experimental studies. it can provide a practical and effective biomaterial for the treatment of clinical skin wound structure and function reconstruction, make the patient's wound healing as soon as possible, benefit the general public, reduce medical expenditure, reduce the burden on the society, lay the foundation for the industrialization and marketization of national innovative medical devices, and help to improve the international status and value of the application.


Eligibility criteria:
inclusion criteria: * age between 18 and 90 years; type 1 or type 2 diabetes mellitus; history of ulceration for more than 4 weeks at enrollment; wound area between 1 and 25 square centimeters; wound depth of wagner grades 1 and 2; and an abi of 0.7 to 1.3 on the affected lower extremity or a transcutaneous oxygen pressure of greater than or equal to 30 mmhg. exclusion criteria: * wound healing percentage greater than 30% during wound preparation (7 days); any infection, osteomyelitis, or other condition that may affect wound healing, such as deep vein thrombosis, rheumatoid arthritis, systemic lupus erythematosus, or any other systemic inflammatory disease.
escitalopram in schizophrenia in ocd- open label study

Conditions: Schizophrenia

Summary: ssri's has been demonstrated to be partially effective in schizophrenia and ocd. we therefore suggest that escitalopram up to 20 mg /d in those patients could be effective in reducing obsessive compulsive symptomatology


Eligibility criteria:
inclusion criteria: * patients who suffer from schizophrenia and ocd exclusion criteria: * substance abuse, * serious medical condintions, * being on ssri treatment
repetitive transcranial magnetic stimulation (rtms) in the treatment of gambling disorder in indonesia

Conditions: Gambling Disorder

Summary: research has shown that cognitive-behavioral therapy (cbt) is an effective treatment for gambling disorder. several studies had also been done to evaluate the effectiveness of repetitive transcranial magnetic stimulation (rtms) in addiction management, particularly in alleviating craving. a randomised controlled trial (rct) of 30 subjects would be conducted to evaluate the effectiveness of transmodalistic therapy with a combination of rtms and cbt for online gambling disorder.


Eligibility criteria:
inclusion criteria: * subjects with pathological gambling (sogs score ≥ 5) * subjects aged 18-59 years old * subjects who understand bahasa indonesia * subjects who agree to participate and receive treatment exclusion criteria: * subjects with history of psychotic disorder, personality disorder, or sleep disorder according to icd-11 * subjects with history of neurostimulation * subjects with history of medical implant * subjects with history of severe neurological disorder, which causes seizure or loss of consciousness * subjects with intellectual disability * subjects with endocrinological disorders * subjects with contraindication during prior mr or other related procedures * subjects who are currently or expecting pregnancy * subjects with history of substance use in the last 6 months